CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.
Michael Schweizer, MD
Advertisement
Articles by Michael Schweizer, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
